$97M Series D Backed by Strategic Investors Across the Oncology Ecosystem Positions Thyme Care to Break Through Cancer Care's Biggest Bottlenecks

• Thyme Care achieves profitability, manages more than $5B in oncology spend, and extends access to 8M people nationwide in a landmark year of growth through new Medicare, commercial, and employer contracts 
• With national scale and measurable outcomes, Thyme Care is positioned to take on more breaking points across the cancer journey and build an integrated oncology infrastructure grounded in value, accountability, and a better patient experience
• As cancer rates climb, Thyme Care dismantles barriers to care with an AI orchestration layer that leverages its connectivity across the cancer ecosystem to reduce cognitive overload on care teams, accelerate stakeholder integration, and deliver timely, personalized support to patients

NASHVILLE – September 25, 2025—Thyme Care, the leading value-based cancer care enabler, today announced a $97M Series D fundraise from current investors CVS Health® Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures. New strategic investors include Morgan Health, a division of JPMorganChase focused on employer-sponsored healthcare, as well as Humana, Texas Oncology, and Memorial Hermann Health System, bringing Thyme Care’s total capital raised to $275M. 

“This raise is overwhelmingly backed by strategic investors across the oncology care delivery landscape, including payers, providers, employers, and health systems who deeply understand the complex needs of oncology populations and who see firsthand the impact of Thyme Care’s model,” said Thyme Care President and Chief Operating Officer Brad Diephuis, MD. "This is evidence that oncology can lead the way in building scalable models of shared accountability and impact that healthcare has long needed.”

“The system was not designed for people with cancer, and too often patients fall through the cracks,” added Thyme Care Chief Executive Officer and Co-Founder Robin Shah. “My co-founder, Dr. Bobby Green, and I have seen this from the inside out for decades. We’ve witnessed it at the bedside in community practices and in building national infrastructures at Flatiron Health and OneOncology, and we founded Thyme Care to change it. Our next chapter is about scaling what works while exploring new ways to tackle the barriers that still make cancer care harder than it needs to be.”

Since its founding in 2020, Thyme Care has grown from concept to market leader by creating an integrated oncology infrastructure that reduces friction across the system. Thyme Care aligns incentives through partnerships with payers so that the best care for patients is also the most sustainable for the system. Working closely with more than 1,000 oncologists nationwide, Thyme Care reduces administrative burden, supports higher-value drug choices, strengthens clinical collaboration, and integrates services such as palliative care and survivorship uniquely into its model. For people with cancer, this fills the gaps and challenges they face day in and day out and translates to earlier interventions, fewer delays, and continuous support throughout the cancer journey. Together, these elements, powered by a purpose-built technology stack and high-performing care teams, enable earlier action, deeper engagement, and position Thyme Care as the backbone enabling oncology care to be more connected and scalable. 

Thyme Care’s impact demonstrates systemic transformation across cost, experience, and provider efficiency, including:

• Creating a more connected and compassionate cancer journey: ~90% of members report feeling more supported with Thyme Care's team of doctors, nurses, oncology social workers, and care partners. This connection ensures no one feels alone in their cancer journey. Because of that trust, 72% of members proactively share updates through electronic patient-reported outcome surveys (ePROs), nearly double the industry average, enabling faster interventions and more connected, compassionate care.
• Avoiding costly complications: Many hospital visits for people with cancer stem from symptoms like pain or nausea that can be safely managed at home with timely support. By intervening earlier, Thyme Care helps patients save time, energy, and money while allowing providers to focus on the highest-value care. Members who completed ePRO surveys were 40% less likely to visit the ER and had 19% fewer hospital admissions.
• Reducing provider burden: Oncology practices face rising volumes and administrative demands that pull providers away from patients. Thyme Care lightens the load by taking on time-consuming administrative and care coordination tasks, freeing capacity to focus on patient care. One Thyme Care Oncology Partner practice saved nearly 2,000 hours of staff time in a year, illustrating how Thyme Care enables providers to focus on what matters most: delivering high-quality, hands-on care.

With proven results at scale, Thyme Care is poised to target more breaking points in the oncology journey, with artificial intelligence—already deeply integrated into Thyme Care’s model—becoming a critical accelerant. By automating documentation, surfacing real-time insights and next-step guidance, and synthesizing complex patient data, AI can reduce the cognitive load on care teams and present the right insights at the right time. The result is more time to focus on people rather than paperwork, and a system that feels more connected and supportive for patients. In doing so, AI evolves from a useful tool into an invisible operating layer that makes high-quality, scalable cancer care possible.  

“Employers increasingly identify cancer as a top driver of their health care spend. At the same time, they care deeply about offering their employees access to high-quality, personalized cancer care – given the heavy burden that a diagnosis places on patients and their families,” said Dan Mendelson, CEO of Morgan Health. “Thyme Care can balance these needs and is already making early progress with Fortune 500 companies. They’ve demonstrated better coordination of patient care, improved outcomes and reduced costs. This approach aligns directly with our mission to scale specialist-led, value-based care for complex conditions in employer-sponsored insurance.”

“We continue to invest in Thyme Care because of the meaningful impact their model has on improving the lives of people with cancer,” said Vijay Patel, managing partner, CVS Health Ventures. “Through their technology, partnerships, and national scale, we’ve seen how Thyme Care can help deliver more coordinated interventions and a care experience that feels more connected, human, and affordable.” 

About Thyme Care 

Thyme Care is the leading value-based care enabler, collaborating with payers and providers to transform the experience and outcomes for individuals living with cancer. The company partners with health plans, employers and risk-bearing providers to assume accountability for enhanced care quality, improved health outcomes, and reduced total cost of care. Thyme Care's approach combines a technology-enabled Care Team and seamless integration with providers, creating a hybrid collaborative care model that guides and supports the entire patient journey. Thyme Care empowers oncologists nationwide through purpose-built tech, advanced data analytics, and virtual patient engagement, driving better care and outcomes in value-based arrangements. To learn more about how Thyme Care is enabling the shift to value-based care in oncology, visit https://www.thymecare.com/ 

Contact 

Kimberly Dreisinger 

Thyme Care Communications 

kimberly@thymecare.com